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Abstract
The Human Proteome Project (HPP) annually reports on progress throughout the field in credibly 
identifying and characterizing the human protein parts list and making proteomics an integral part 
of multi-omics studies in medicine and the life sciences. neXtProt release 2018–01-17, the 
baseline for this 6th annual HPP special issue of the Journal of Proteome Research, contains 
17,470 PE1 proteins, 89% of all neXtProt predicted PE1–4 proteins, up from 17,008 in release 
2017–01-23 and 13,975 in release 2012–02-24. Conversely, the number of neXtProt PE2,3,4 
missing proteins has been reduced from 2949 to 2579 to 2186 over the past two years. Of the PE1 
proteins, 16,092 are based on mass spectrometry results, and 1378 on other kinds of protein 
studies, notably protein-protein interaction findings. PeptideAtlas has 15,798 canonical proteins, 
up 625 over the past year, including 269 from SUMOylation studies. The largest reason for 
missing proteins is low abundance. Meanwhile, the Human Protein Atlas has released its Cell 
Atlas, Pathology Atlas, and updated Tissue Atlas, and is applying recommendations from the 
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International Working Group on Antibody Validation. Finally, there is progress using the 
quantitative multiplex organ-specific popular proteins targeted proteomics approach in various 
disease categories.
Graphical Abstract
Identified and predicted proteins by PE level in neXtProt release 2018–01-17.
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INTRODUCTION
The Human Proteome Project (HPP) of the Human Proteome Organization (www.hupo.org) 
has provided a framework for international communication, collaboration, quality assurance, 
data sharing, and acceleration of progress in the global proteomics community since its 
announcement in 2010 and launch in 2011. The HPP has two over-arching goals: (1) 
completing the human protein parts list tied to predicted protein-coding genes as curated by 
neXtProt and updated annually in this HPP Metrics publication; and (2) integrating 
proteomics with genomics and other omics for use throughout the biomedical/life sciences 
community, led by the Biology and Disease-driven HPP. The parts list starts with at least one 
HPP Guidelines-compliant identification of a protein product matching the predicted 
sequences and expands through detection and characterization of the functions of splice 
variants, sequence variants, post-translational modifications, and protein-protein 
interactions. The omics integration has been facilitated through development of targeted 
proteomics, including the SRMAtlas and DIA/SWATH-MS, combined with bibliometric 
analyses that identify popular proteins widely studied in biomedical research.
There are 50 research teams worldwide organized by chromosome, mitochondria, biological 
processes, and disease categories plus resource pillar groups for affinity-based protein 
capture, mass spectrometry, knowledge bases, and, most recently, pathology. This 
Perspective introduces the sixth annual HPP special issue of the Journal of Proteome 
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Research1–6, with emphasis on the identification of neXtProt PE2,3,4 missing proteins 
(MPs) led by the Chromosome-centric C-HPP.
PROGRESS ON THE HUMAN PROTEOME PARTS LIST
neXtProt release 2018–01-17 (www.nextprot.org) and PeptideAtlas v2018–01b 
(www.peptideatlas.org), using HPP Guidelines for Interpretation of MS Data v2.17 
(hupo.org/Guidelines), provided the baseline for HPP investigators and other scientists 
around the world to prepare manuscripts on MPs and other topics for this 2018 special issue. 
Full datasets and metadata are shared with the community through the ProteomeXchange 
Consortium repositories PRIDE, PASSEL/SRM, MassIVE, jPOST, and iProX as described 
in 20164. ProteomeXchange8 as of 2018–05-15 had 5248 publicly-released data sets, of 
which 2165 are from human samples, up from 3496 and 1478, respectively, one year ago 
(http://proteomecentral.proteomexchange.org/).
neXtProt release 2018–01-17 updated its validation of PE1 proteins to 17,470, an increase of 
462 from release 2017–01-23 (see Table 1 for definitions and data). In 2013–2014 we 
excluded the “uncertain/dubious” genes of PE5 in our denominator of predicted proteins to 
be detected3. Thus, the number of missing proteins (MP = PE2+3+4) has been reduced to 
2186 from 2579 a year ago, 2949 two years ago, and 5511 in 2012. The PE1 proteins now 
constitute 89% of the total PE 1,2,3,4 predicted proteins.
Meanwhile, the number of canonical proteins in PeptideAtlas increased during 2017 by 625 
to reach 15,798, or 98% of the neXtProt figure of 16,092 PE1 proteins based on MS (see 
Table 1).
Figure 1 provides a detailed depiction of the changes within neXtProt by PE categories 
during the year from release 2017–01-23 to release 2018–01-17. There were 91 proteins 
added to neXtProt, due to their addition to UniProtKB/Swiss-Prot; 44 were qualified as PE1, 
while 40 were added as PE2,3, or 4 MPs, and 7 as PE5. Among the new PE1 proteins are 
four sORFs with strong proteomics evidence - ASDURF (NX_L0R819), NBDY 
(NX_A0A0U1RRE5) and SLC35A4 and MIEF1 upstream open reading frame proteins 
(NX_L0R6Q1 and NX_L0R8F8); the recently characterized LINC00961-encoded SPAR 
polypeptide (NX_A0A1B0GVQ0); and three chimeric proteins with biological activity – 
IQCJ-SCHIP1 (NX_B3KU38), CSB-PGBD3 (NX_P0DP91) and BARGIN (NX_Q6ZT62). 
Among the new PE3 proteins is the sORF Minion (NX_A0A1B0GTQ4), recently 
characterized in mouse but still lacking transcriptomic or proteomic evidence in human. 
Further curation led to deletion of 10 PE1, 3 PE2,3,4 missing proteins, and 7 PE5 dubious 
entries. The net effect was expansion of neXtProt entries by 71 proteins. The biggest change 
by far is the movement of 431 PE2,3,4 proteins into PE1, due to additional MS evidence 
reflected in the large increase of canonical proteins in PeptideAtlas and other high quality 
data at protein level. ZNF804A, GAGE12G and CEACAM19 were previously validated as 
PE1 due to PPI and characterization data, but these data have been removed from 
UniProtKB/Swiss-Prot, resulting in their downgrade to MP status. Finally, four entries were 
lifted from PE5 status to PE2,3,4, while six MPs were downgraded to PE5 status; none 
moved from PE5 to PE1.
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UniProtKB/Swiss-Prot and neXtProt integrate manually curated protein-protein interaction 
(PPI) data from the IntAct database9. These data are primarily based on Yeast Two Hybrid 
(Y2H) methods, supplemented by affinity purification/mass spectrometry (AP/MS), phage 
display, and co-immunoprecipitation. To validate a protein as PE1 based on PPI data, 
UniProtKB/Swiss-Prot and neXtProt use a subset of PPI data from IntAct (labeled as Gold 
in neXtProt). This subset is built by IntAct using a scoring system detailed at https://
www.ebi.ac.uk/intact/pages/faq/faq.xhtml#4 with weighting of different kinds of 
experimental evidence. These criteria ensure that only experimental data are used and there 
are always at least two experimental datasets to reach the threshold score to trigger a PE1 
upgrade. Moreover, the upgrade cannot be triggered if the protein pair only co-occurs in 
larger complexes as detected by AP/MS, because there must be at least one indication that 
the proteins are in physical contact. Currently, 530 PE1 protein validations are based on 
“Gold” PPI, up from 372 a year ago. Y2H methods utilize artificially-expressed bait proteins 
to detect protein interaction partners. Generally, this approach does not identify the tissues of 
expression or guide researchers to a choice of biological specimens to study; however, preys 
may be selected from a library of transcripts expressed in a particular tissue.
Using the neXtProt “Interactions” view, https://www.nextprot.org/entry/NX_O60479/
interactions, users can look for the Gold Protein-Protein interactions for each of the proteins 
of interest to see the number of experiments behind each interaction. Clicking on the 
“evidence” button will link to the IntAct page with details about the experimental datasets 
used.
The pie chart (Figure 2) shows the nature of the evidence data for PE1 proteins, as well as 
the numbers in other categories as of neXtProt release 2018–01-17. There are 16,092 PE1 
proteins identified with MS data compliant with HPP Guidelines, of which 98% are 
canonical in PeptideAtlas. There are 1378 additional PE1 proteins identified with other 
kinds of protein evidence: 99 by Edman sequencing, 176 by disease mutations, 75 from 3D 
structures, 530 by protein-protein interactions, 58 with Ab-based techniques, 170 from 
PTMs or proteolytic processing, and 270 from other biochemical studies. PE2,3,4 missing 
proteins are divided into those with no MS data (1798) and those with insufficient or 
unconfirmed MS data (388, down from 453 in 2017 and 485 in 2016), primarily due to the 
application in 2016 of the more stringent HPP Guidelines7 for accepting MS-based 
identifications. Nearly 100 of those excluded in 2016 have been restored as additional data 
have been reported and reviewed.
EXPANSION OF PEPTIDEATLAS FROM 2017 to 2018
The canonical proteins in PeptideAtlas increased from 15,173 to 15,798 during the year 
from v2017–01 to v2018–01. Of the 40 MS datasets that were added to the PeptideAtlas 
Human Build during 2017, eight provided 528 of the 625 proteins that were newly validated 
as canonical (Figure 3). Often these datasets and publications provided a second uniquely 
mapping non-nested peptide with length ≥9 amino acids, raising the corresponding protein 
to canonical status. In some cases, the datasets provided both peptides. The greatest 
contributions came from studies that enriched for proteins that had not been well-represented 
previously, including SUMOylated proteins, membrane proteins, and zinc finger proteins. 
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PeptideAtlas would contain 273 fewer canonical proteins if PTM-containing peptides were 
excluded. PTMs are the primary focus of the HPP MS resource pillar, including an ongoing 
community project with a specially-prepared sample of 96 phosphopeptides. Both neXtProt 
and PeptideAtlas have growing content of PTMs as noted by Omenn et al5. A major advance 
is the introduction of MSFragger for ultra-fast identification of post-translational and 
chemical modifications of peptides (Kong et al10). An extensive review of human 
proteoforms has recently been published11.
THE FATE OF MISSING PROTEINS NOMINATED FOR neXtProt REVIEW IN 
THE JPR 2017 PAPERS
The editorial for the JPR 2017 special issue12 highlighted six papers that used a variety of 
promising methods to find Missing Proteins, with a total of 32 identified for validation as 
PE1: 15 from Li et al13 using Triton X-100 solubilization plus ProteoMiner hexapeptide-
covered beads as an enrichment/equalization strategy for low-abundance proteins with 
kidney, bladder, liver, and colorectal specimens, and confirmation with PRM; 12 from 
Carapito et al14 on the sperm proteome with PRM confirmation; 3 from Wang et al15 using a 
multi-protease strategy on testis; 1 from Peng16 from the kidney phosphoproteome; 1 from 
Meyfour et al17 based on biological studies of a Y chromosome protein in cardiac 
development; plus 41 cautiously forwarded from Elguoshy et al18 using the stranded 
peptides approach described below. Twenty MP reported by Li et al8, including 5 without 
PRM validation that had not been counted in the editorial, are now classified as canonical in 
PeptideAtlas and validated as PE1 in neXtProt. Only 4 from Carapito et al14 were validated 
as PE1, because the review of PRM data at PeptideAtlas was incomplete, as was the 
consideration of immunochemistry results using antibodies obtained from HPA. From the 
list of proteins reported by Wang et al,15 only P0DMU9 was validated as PE1, and that was 
based on unrelated data for 5 proteotypic peptides not reported by Wang et al15. Beta-
defensin 123 (Q8N688) may be a candidate for a policy discussion of implementation of the 
Guidelines exceptions clause7, because there are excellent spectra for all of the three 
potential proteotypic tryptic peptides, but two are only 8 aa in length. SIM1 from Peng et 
al16 was validated. TBL1Y proposed by Meyfour et al17 was validated, but based on other 
MS data. The Elguoshy et al18 data, which lacked PXD identifiers, could not be considered 
by PeptideAtlas and neXtProt, but 16 of their proposed proteins were coincidentally 
promoted to PE1 from other datasets.
In sum, through various paths, 43 of the 73 MP candidates recommended from the 2017 JPR 
special issue have to date qualified as PE1 by neXtProt. It takes a village!
With the pace in MP identification seeming to decline as the “more easily detected proteins” 
had been identified by conventional strategies, the C-HPP and HPP announced at the Sun 
Moon Lake HPP Workshop after the HUPO World Congress in Taiwan in September 2016 a 
“MP50 Challenge” to accelerate identification of 50 PE2,3,4 missing proteins per 
chromosome team over two years. While some teams are still in planning phases, work from 
the entire proteomics community has raised 952 MPs to PE1 status since neXtProt release 
2016–01-11 (see Table 1), including the notable completion of the mitochondrial 
Omenn et al. Page 5
J Proteome Res. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
chromosome with its 15th protein by the Italian team19. Barriers include limited temporal 
and spatial expression of proteins important in fetal development, disease responses, rare 
cell types, and difficulties to access tissues. Of course, the more stringent guidelines 
introduced in 2016 appropriately raised the bar for MP identification from MS.
Two new situations have arisen with regard to the standardized reanalysis of datasets by 
PeptideAtlas. First, as illustrated above, some labs use PRM instead of SRM for comparison 
of natural and synthetic peptides. PeptideAtlas, which several years ago developed PASSEL 
for extensive SRM data, has now begun to process PRM data. The second development was 
the strategy of the Chromosome 7 team (Baker et al20) and the Chromosome X team 
(Elguoshy et al18) to identify what we have named “stranded peptides” in major databases 
that could be combined to make a pair of proteotypic peptides for individual missing 
proteins and then use the reported spectra from the original work (preferably deposited in 
PRIDE or other accessible repository with a PXD identifier) to compare with the spectra 
available in SRMAtlas21 for the corresponding synthetic peptide. This work will be 
facilitated by development of a Universal Spectrum Identifier, soon to be released by 
PeptideAtlas and PSI. Peptides in PeptideAtlas have been validated. There may be many 
stranded peptides from different studies in GPMdb, MassIVE, Proteomics DB, or other 
resources. There is no automated connector between GPMdb and either PeptideAtlas or 
neXtProt; they use different reference genomes and have other incompatible features. Thus, 
use of stranded peptides from GPMdb requires search within GPMdb for the original source 
and links to ProteomeXchange PXD identifiers and to original spectra and metadata. Making 
the case, including careful scrutiny of the original MS spectra, is the responsibility of 
authors; requests to original MS data generators seeking their re-submission of original data 
to ProteomeXchange may be useful in some cases.
SEEKING PE2,3,4 MISSING PROTEINS IN MAJOR PROTEIN FAMILIES
Hydrophobic proteins are estimated to account for 924 of the 2186 MPs (Zhang et al22). 
Thus, techniques to extract and solubilize these proteins remain a key need. Many of these 
proteins are members of six major protein families, as shown in Figure 4. NeXtProt releases 
for 2013, 2016, 2017, and 2018 were downloaded for Chromosomes 1–22, X, Y, and 
mitochondria; PE2–4 MPs were sorted alphabetically according to protein families or 
groupings and confirmed through UniProtKB, Pfam, and GeneCards. Miscellaneous 
“uncharacterized proteins” were excluded. Figure 4 summarizes the progression of findings 
for the top six PE2,3,4 missing protein families: (i) olfactory receptors (ORs), (ii) non-OR 
transmembrane proteins, (iii) zinc finger proteins, (iv) homeobox proteins, (v) keratin-
associated proteins, and (vi) coiled-coil proteins. Membrane proteins annotated as olfactory 
receptors and as other transmembrane proteins (including non-OR GPCRs, taste receptors 
and solute carrier proteins) are now the two most abundant PE2–4 families. Non-OR 
transmembrane proteins have overtaken zinc-finger proteins, as a significant number of zinc-
finger proteins were re-classified as PE1 between 2017 and 2018 (see Adhikari et al23). The 
only top-six protein family where no progress has been made to identify proteins by MS is 
ORs; taste receptors also show little progress (Adhikari et al23). Rare ORs (OR1D2, 
OR3A4) have reached PE1 status through protein-protein interaction analyses (see Siddiqui 
et al24). There are no credible OR detections in PeptideAtlas.
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RECOGNIZING THE LIMITATIONS OF FINDING PE2,3,4 MISSING PROTEINS
As of neXtProt release 2018–01-17 there were still 2186 PE2,3,4 missing proteins. This 
Perspective analyzes the progress reflected in the 2018 release: 462 new PE1 proteins, 
including 158 based on protein-protein interactions via IntAct, and 625 new canonical 
proteins from mass spectrometry in PeptideAtlas, including a very large contribution of 269 
from one study of the post-translational modification SUMOylation (see Figure 3, above). 
The Editorial that will accompany the published articles from this year will identify 
additional progress.
The major limitations in finding more PE2,3,4 missing proteins remain (1) protein sequences 
that cannot yield two proteotypic tryptic peptides, (2) lack of detectable expression of 
transcripts in tissues studied, and (3) concentrations of proteins too low to be detected with 
even the recently greatly-enhanced mass spectrometers plus enrichment with such steps as 
ProteoMiner hexapeptide beads.
Of the 2186 PE 2,3,4 missing proteins (each lacking any or sufficient MS evidence to meet 
the HPP Guidelines), only a small number may not be unambiguously detectable with 
current mass spectrometry techniques, if the transcript is expressed and the protein has 
sufficient abundance. We performed the following exercise to estimate that number. Using 
in-silico digestion of the PE1–4 proteome with trypsin without considering missed 
cleavages, we find that only 141 PE1 proteins (0.8%) and 79 PE2,3,4 proteins (3.6%) cannot 
potentially generate two non-nested uniquely mapping tryptic peptides of length 9–50 amino 
acids (after removing 54 sequence-exact duplicates, clipping initiating methionines or signal 
peptides, and treating isoleucine = leucine, I=L). Trans-membrane region issues are not 
considered in the computation. Moreover, when a set of five common proteases (trypsin, 
chymotrypsin, AspN, GluC, LysC) is applied in the same approach, we find that a mere 13 
proteins cannot potentially generate the requisite two non-nested uniquely mapping peptides 
of length 9–50 amino acids. Remarkably, of those 13 proteins, 6 are already PE1 in 
neXtProt, mostly via other technologies, including Ataxin-8 (Q156A1), whose sequence has 
all glutamines (79Q). One of these six seemingly MS-unattainable PE=1 proteins (C9JFL3), 
with only a single lysine and no arginines, is canonical in PeptideAtlas due to several well-
detected non-nested peptides that are semi-tryptic. Thus, if a protein is sufficiently abundant, 
imperfect cleavage may provide suitable peptides to meet the HPP guidelines. Under-
digesting or over-digesting with trypsin itself may be a useful tactic. The issues around 
membrane-bound proteins do complicate the picture, but in PeptideAtlas there are also many 
canonical detections of proteins that seem unattainable by following strict protease rules 
around trans-membrane regions. We conclude that nearly all proteins could, in principle, be 
detectable by mass spectrometry following current HPP MS Guidelines with reasonable 
additional effort if the proteins are of sufficiently high abundance in an analyzed sample. We 
recognize that selective enrichment techniques (including affinity capture) will be essential 
for many of the remaining MPs to achieve the necessary abundance for detection with MS.
Of course, it is unlikely that proteins will be found in specimens that have undetectable or 
very low levels (<1 FPKM) of the corresponding transcript. An initial assessment of 
transcript data from Human Protein Atlas, GTEx, FANTOM5, and TCGA suggests that as 
many as 800–1000 PE2,3,4 predicted protein-coding genes may be lacking detectable 
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transcripts in all tissues tested (J. Schwenk, preliminary analyses). There are 400 predicted 
olfactory receptors that are such missing proteins (Figure 4); Hwang et al25 were unable to 
detect expression of even one olfactory receptor protein in human olfactory epithelium.
There remain many under-investigated types of specimens, including unusual tissue types, 
embryonic and fetal stages of life, and responses to oxidative or inflammatory stress. The 
Chr 2/14 French/Swiss consortium has exploited the knowledge of exclusive expression of 
hundreds of transcripts in male reproductive tract by performing deep studies of 
sperm14, 26–27, complemented by studies of testis by the Chinese team15, 28, 29–30. Other 
examples are dental pulp31, male fetal cardiac development17, kidney and bladder16, and 
beta-defensins32. The Chromosome 17 team has analyzed how 43 previously MPs have been 
identified as PE1 since the announcement of the MP50 Challenge and identified 35 of the 
remaining 105 MPs as amenable to identification by MS or protein-protein interactions24.
FINDING EVIDENCE FOR FUNCTIONAL ANNOTATION OF 
UNCHARACTERIZED neXtProt PE1 PROTEINS
A comprehensive understanding of the human proteome requires not just the “parts” list and 
their interactions, but deep knowledge of their functions in health and disease. Notably, 
according to neXtProt release 2018–01-17, 1937 PE1,2,3,4 proteins lack specific functional 
annotation, including 1260 uncharacterized PE1 proteins (uPE1) (https://tinyurl.com/
upe1proteins) and 677 uncharacterized missing proteins (PE2+PE3+E4). C-HPP 
investigators agreed in September 2017 at the HPP meeting in Dublin to launch a project 
focused on characterization of the functions of proteins and proteoforms, not just stringent 
identification of their expression33. Deep-dive biological studies are strongly encouraged; an 
example is Na et al34. According to Paik et al33, 14 C-HPP teams have committed to begin 
work on selected uPE1 proteins. The Chromosome 17 team is exploiting a computational 
approach using I-TASSER and COFACTOR algorithms for prediction of protein 
functions35.
2018 UPDATE OF THE HUMAN PROTEIN ATLAS
At the end of 2017, the Human Protein Atlas (HPA) released version 18 (based on Ensembl 
version: 88.38), which included 26,009 antibodies, targeting proteins from almost 17,000 
human genes (~87% of the human protein-coding genes). The HPA now presents three 
major atlases: The Tissue Atlas36, the Cell Atlas37, and a Pathology Atlas38. The Tissue 
Atlas added data for caudate nucleus and thymus. The Cell Atlas was expanded by data from 
RNA sequencing of 8 cell lines and increased the panel for immunofluorescence staining to 
26 cell lines, as well as introducing cleavage furrow as an annotated structure. The 
Pathology Atlas integrates mRNA expression levels from 17 cancer types and 8000 patients 
hosted by The Cancer Genome Atlas39, links the expression of protein-encoding genes to the 
overall survival time for each patient, and complements these insights with protein level data 
from immunohistochemistry. Based on Kaplan-Meier analysis, elevated relative mRNA 
expression of 6800 genes correlated with poor prognosis in at least one of the analyzed 
cancer types, while elevated relative mRNA expression of about 6100 genes was linked to 
good prognosis.
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The HPA portal also integrated the latest guidelines regarding the validation of antibodies, 
using “enhanced validation” criteria as defined by its International Working Group40. A total 
of 10,540 antibodies in the HPA v18 (40%), targeting 6,787 human proteins, now have 
enhanced validation data from analyses of cells or tissues with immunocytochemistry, 
immunohistochemistry, and Western blots. The five validation procedures are: (i) before and 
after knock-down of target genes (denoted genetic validation), (ii) induced overexpression or 
fluorescent tagging of proteins (recombinant expression validation), (iii) comparison of 
staining pattern with two antibodies targeting different epitopes (independent antibody 
validation), (iv) antibody-free methods (orthogonal validation), and (v) relating the staining 
pattern and determined protein size with a capture MS method (capture MS validation). As 
illustrated with a set of 197 antibodies, this validation process is complex and painstaking, 
including recognition of significant batch-to-batch variation41.
NOTABLE THRUSTS IN THE USE OF PROTEOMICS FOR BIOLOGICAL AND 
DISEASE STUDIES, AN UPDATE FROM THE B/D-HPP
One of the main goals of the Biology and Disease-driven Human Proteome Project (B/D-
HPP) is to reveal the molecular basis of physiological/pathological processes by identifying 
the driver proteins involved. To guide organ and biofluid studies, B/D HPP initiatives have 
been encouraged to utilize lists of “popular proteins” (highly cited proteins associated with 
the organ or other topic of interest) to generate functional hypotheses and to pave the way 
for new clinical applications of targeted proteomics. Two web tools have been developed to 
perform systematic bibliographic searches and rank the most cited proteins under specific 
topics (Lam et al42; Yu KS et al43). The popular protein approach has been used in two 
studies demonstrating the principal role of reconfiguration of one carbon metabolism in the 
liver during hepatocarcinogenesis44 and creating a targeted assay to monitor B-type 
natriuretic peptidoforms that might be biomarkers for diagnosing and monitoring heart 
failure45.
Characterization of proteoforms and PTMs is an unmet need to understand the dynamics of 
pathogenic processes. A novel mass spectrometry-based whole protein assay enabled 
quantitation of the percentage of mutant KRAS4b present in colorectal cancer tissue, and the 
differences on C-terminal carboxymethylation, which is critical for KRAS function46. 
Understanding PTM status of drug targets and the functional implications is key to next 
generation therapies. Van Eyk et al47 have shown that S-nitrosylation of GSK3B at specific 
residues can send the protein to the nucleus, away from its cytoplasmic location, resulting in 
a different repertoire of phosphorylated substrates and altering responses to drugs47.
The detailed description of the array of peptides associated with human HLA phenotypes is 
of paramount importance to understand the immune system and to guide the development of 
next-generation vaccines and immunotherapies against autoimmunity, infectious diseases, 
and cancers. Mass spectrometry is the only available technology to interrogate the 
immunopeptidome in an accurate, systematic, unbiased manner. The Human 
Immunopeptidome Proteome Project (HIPP)48 has developed the first public database of 
quality-controlled immunopeptidomic data generated by mass spectrometry49. The 
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combination of MHC isolation, peptide analysis, and exome sequencing facilitates 
identification of immunoglobulin neoantigens as targets for lymphoma50 and ovarian 
cancer51 immunotherapy and opens new avenues for individualized immunotherapies.
One of the principal aims of the B/D-HPP is to better understand human organ physiology 
and pathology through comprehensive proteomic insights. To this end, eye and plasma 
proteomes have been updated recently. A total of 9782 non-redundant proteins (not 
necessarily compliant with HPP guidelines) are now in the human eye proteome database of 
11 tissue compartments plus biofluids, with the highest number (6538) from vitreous humor 
and the lowest (827) from aqueous humor52. More than 122,000 peptide sequences matching 
to 3509 protein identifications compliant with the HPP guidelines are described in the 2017 
Plasma Peptide Atlas53.
The B/D HPP community has sought to identify protein biomarkers in multiple clinical 
fields, including Pediatrics54 and Rheumatoid and Autoimmune Disorders such as knee 
osteoarthritis55 and osteoarticular pathologies with MS56 or protein arrays57, 58, and 
rheumatoid arthritis with anti-citrullinated protein antibodies58. In-depth analyses of the 
synaptosomal proteome led to association of specific protein expression patterns with social 
behavior in patients with schizophrenias59, through a joint C-HPP (chromosome 15) and 
B/D HPP (Brazilian Brain initiative) effort. Similar cooperation led to a comprehensive 
description of the human mitochondrial proteome under standardized protocols19, to assess 
the pharmacological prospects of targeting specific mitochondrial proteins to selectively kill 
cancer cells60. Cancer biomarker discovery has experienced significant progress, as shown 
by the recent studies of breast, ovarian, and colorectal cancers published by members of the 
Cancer B/D-HPP and NCI CPTAC initiative61–63. Novel DIA MS-based and proteogenomic 
approaches have facilitated discovery of new protein species and splice variants that can be 
used to improve colorectal cancer screening64, 65 and point to therapeutic targets in breast 
cancers66. Finally, realizing that food allergy is a global health concern, the pros and cons of 
current analytical methods for allergenic risk assessment have been reviewed by members of 
the Food and Nutrition B/D-HPP initiative67; this group also evaluated state-of-the-art 
proteomic and metaproteomic approaches to study host-microbiome interactions68.
As noted above, productive interaction between HPP groups is shedding light on many 
relevant aspects of human biology. Such cooperative multi-omics efforts should guide next 
steps in our endeavor to generate a comprehensive human proteome map with all functional 
annotations needed to decipher the code of life and support future molecular precision 
medicine.
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Figure 1. 
This flow chart depicts the changes in neXtProt PE1–5 categories from release 2017–01-23 
to release 2018–01-17. There are 431 missing proteins promoted to PE1 and 44 new 
SwissProt proteins added as PE1 proteins, while 3 PE1 proteins were demoted to PE2,3,4 
MPs and 10 PE1 proteins were deleted altogether. See text for further discussion.
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Figure 2. 
Identified and predicted proteins by PE level in neXtProt release 2018–01-17.
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Figure 3. 
These eight datasets added to PeptideAtlas in 2017 provided the evidence needed to raise the 
PeptideAtlas protein category to “canonical” for more than 10 proteins each. Canonical 
status requires two or more uniquely-mapping non-nested peptides with length ≥9 residues 
with high-quality spectra, not accounted for by sequence variants or isobaric PTMs in other 
proteins. PXD identifiers refer to ProteomeXchange.8
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Figure 4. 
Progress on identification of members of the six most numerous protein families in neXtProt 
Missing Protein categories PE2,3,4 from 2013 to 2018 (updated from Baker et al20).
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Table 1.
neXtProt protein existence evidence levels from 2012 to 2018 showing progress in identifying PE1 proteins 
and PeptideAtlas canonical proteins. More stringent guidelines imposed in 2016.
PE Level
Feb
2012
Sept
2013
Oct
2014
April
2016
Jan
2017
Jan
2018
1: Evidence at protein level 13,975 15,646 16,491 16,518 17,008 17,470 a
2: Evidence at transcript level 5205 3570 2647 2290 1939 1660 2186
Missing
Proteinsb
3: Inferred from homology 218 187 214 565 563 452
4: Predicted 88 87 87 94 77 74
5: Uncertain or dubious 622 638 616 588 572 574
 
Human PeptideAtlas canonical proteins 12,509 13,377 14,928 14,629 15,173 15,798
a
Percent of predicted proteins classified as PE1 by neXtProt = PE1/PE1+2+3+4 = 89%.
b
Missing Proteins PE 2+3+4 = 2186, down from 2579 in neXtProt v2017-01.
J Proteome Res. Author manuscript; available in PMC 2019 April 15.
